Jazz Pharmaceuticals JAZZ Increase Decrease In Accrued Income Taxes Payable
Increase Decrease In Accrued Income Taxes Payable at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's increase decrease in accrued income taxes payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's increase decrease in accrued income taxes payable?
- Jazz Pharmaceuticals (JAZZ) reported increase decrease in accrued income taxes payable of $37.4M in Q1 2026.
- How has Jazz Pharmaceuticals's increase decrease in accrued income taxes payable changed year-over-year?
- Jazz Pharmaceuticals's increase decrease in accrued income taxes payable increased by 187.7% year-over-year, from $13M to $37.4M.
- What does increase decrease in accrued income taxes payable mean?
- The change in the amount of income tax the company owes but has not yet paid.
- How do you interpret increase decrease in accrued income taxes payable?
- Changes reflect the timing of tax installments and adjustments to tax provisions based on current earnings.
- How does increase decrease in accrued income taxes payable compare across companies?
- Highly dependent on tax jurisdiction and regulatory filing requirements; varies significantly by company tax strategy.